Doubling Down On Antibiotic Incentives: Congress, Obama Administration Drafting Proposals

The 2012 FDA Safety & Innovation Act included important new incentives for antibiotic developers. But the Obama Administration and key legislators want to do even more to revive R&D in the space. What will it take to bring Big Pharma back?